Axogen
Axogen, Inc., headquartered in the United States, is a leading innovator in the field of regenerative medicine, specialising in peripheral nerve repair. Founded in 2002, the company has made significant strides in advancing surgical solutions for nerve injuries, with a focus on providing high-quality products that enhance patient outcomes. With a robust portfolio that includes Axoguard® Nerve Connector and Avance® Nerve Graft, Axogen stands out for its commitment to utilising human tissue for nerve repair, setting it apart from traditional synthetic alternatives. The company has established a strong market position, recognised for its pioneering contributions to nerve regeneration and repair. Operating primarily in North America, Axogen continues to expand its influence in the medical device industry, driven by a mission to restore function and improve the quality of life for patients suffering from nerve damage.
DitchCarbon Score
How does Axogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Axogen's score of 25 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Axogen's reported carbon emissions
In 2022, Axogen reported total carbon emissions of approximately 1,630,000 kg CO2e. This figure includes about 526,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and approximately 1,104,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Currently, there are no disclosed reduction targets or climate pledges from Axogen, indicating a potential area for future commitment in addressing climate change. As the company continues to operate within the medical technology sector, it is essential for Axogen to consider establishing specific reduction initiatives to align with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 526,000 |
| Scope 2 | 1,104,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Axogen is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
